Pivotal trials and novel combinations have started, but four programmes seem to have been discontinued.
ApexOnco Front Page
Recent articles
Varseta-M efficacy wanes, but more than justifies a pivotal trial.
The Aquila study could make Darzalex the first approved drug for smouldering multiple myeloma.
Enzomenib might be the most promising agent so far, on a cross-trial basis.
The group presents data with bleximenib plus chemo, but looks behind Kura’s contender.
Phase 2 data show why Merck took the lowest dose of zilo-V into phase 3.
Etentamig is one of several anti-BCMA T-cell engagers seeking attention at ASH.
JNJ-89853413 is disclosed as the lead in the two companies' 2020 alliance.
